News
GILD
--
0.00%
--
Gilead picks Amazon Web Services as preferred cloud provider
Gilead Sciences (GILD +0.7%) has selected Amazon Web Services, a unit of tech giant Amazon.com, Inc. (NASDAQ:AMZN), as its preferred cloud provider, according to a statement from the two companies.
Seekingalpha · 11h ago
BRIEF-Gilead And AWS Collaborate On Development And Delivery Of New Medicines For Patients
reuters.com · 12h ago
Gilead and AWS Collaborate on Development and Delivery of New Medicines for Patients
Today, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), announced that Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company advancing innovative medicines to prevent and treat life-threatening diseases, has...
Business Wire · 12h ago
Gilead Says Co's Bold Ambition Of Transforming Triple-Negative Breast Cancer Treatment To Be Highlighted With New Data At SABCS
Gilead Sciences, Inc. (NASDAQ:GILD) will present additional data from the Phase 3 ASCENT study of Trodelvy® (sacituzumab govitecan-hziy) during the upcoming San Antonio Breast Cancer Symposium (SABCS) being held
Benzinga · 13h ago
Gilead’s Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS
FOSTER CITY, Calif., November 29, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) will present additional data from the Phase 3 ASCENT study of Trodelvy® (sacituzumab govitecan-hziy) during the upcoming San Antonio Breast Cancer Symposium (SABCS) being held fro...
Business Wire · 13h ago
Why Are NRx Pharma's Shares Soaring Premarket?
NRx Pharmaceuticals (NASDAQ: NRXP) has completed an analysis in the subgroup of Zyesami and placebo-treated patients previously treated with Gilead Science Inc's (NASDAQ: GILD) remdesivir in the COVID
Benzinga · 13h ago
Ligand's (LGND) Drug-Developing Technologies Holds Potential
Zacks.com · 3d ago
Gilead Sciences (GILD) Stock Gains 20% YTD: What Lies Ahead?
Zacks.com · 3d ago
Gilead, Merck pause trial of once-a-week HIV drug combo
HIV patients already enrolled in the trial will continue to receive the companies' combination therapy.
American City Business Journals · 5d ago
Biotech Stock Roundup: Drug Approvals for BMRN, Updates From BIIB, BMY, MRNA & More
Zacks.com · 5d ago
Gilead (GILD) Gets EU Nod for Breast Cancer Drug, Trodelvy
Zacks.com · 5d ago
A Look Into Gilead Sciences Debt
  Shares of Gilead Sciences (NASDAQ:GILD) fell by 1.76% in the past three months. Before we understand the importance of debt, let us look at how much debt Gilead Sciences has.
Benzinga · 5d ago
Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial
Gilead Sciences Inc (NASDAQ: GILD) and Merck & Co Inc (NYSE: MRK) have 
Benzinga · 5d ago
Gilead's Trodelvy Approved In Europe For Aggressive Form Of Breast Cancer
The European Commission has approved Gilead Sciences Inc's (NASDAQ:
Benzinga · 6d ago
The Importance of Self Advocacy in Breast Cancer: Janelle's Story
Janelle Goins was watching TV one evening when she discovered a small nodule in one of her breasts. But she didn’t feel overly concerned because she’s had cysts in the past.
News Direct · 6d ago
Gilead Sciences' Trodelvy marketing application OK'd in Europe for breast cancer
Gilead Sciences (NASDAQ:GILD) announces that the European Commission (EC) has granted marketing authorization for Trodelvy (sacituzumab govitecan), a Trop-2-directed antibody-drug conjugate, as a monotherapy indicated for the treatment of adult patients
Seekingalpha · 6d ago
BRIEF-Gilead Sciences Says European Commission Grants Marketing Authorization To Breast Cancer Treatment
reuters.com · 6d ago
Trodelvy® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy ® (sacituzumab govitecan), a first-in-class Trop-2-directed antibody-drug conjugate, as a monotherapy...
Business Wire · 6d ago
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 6d ago
Tonix Pharma rises after announcing publication of study on COVID-19 antiviral
Tonix Pharmaceuticals (NASDAQ:TNXP) has added ~9.6% in the post-market after announcing the publication of a paper detailing the results of in vitro studies on sangivamycin, the active pharmaceutical ingredient of the company’s COVID-19 antiviral
Seekingalpha · 11/22 21:52
Webull provides a variety of real-time GILD stock news. You can receive the latest news about Gilead Sciences through multiple platforms. This information may help you make smarter investment decisions.
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.